Asterand to Validate Abcam’s Antibodies | GenomeWeb

NEW YORK (GenomeWeb News) – Asterand said today that it will validate and characterize antibodies and immunohistochemistry applications for antibody marketer Abcam.

Under the collaborative agreement, Asterand will use its PhaseZero Human Tissue Services platform and its Target Evaluator gene expression database to select antibodies and to identify expression patterns for their use with human tissue.

The resulting data will be incorporated into Abcam’s literature and technical support documentation for each antibody tested and will be sold through its online catalogue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.